| Source: |
| Type: |
| A pro-apoptotic protein that plays a crucial role in regulating cell death, particularly in the context of cancer. BIM is a member of the BCL-2 family of proteins, which are key regulators of apoptosis (programmed cell death). BIM cancer is characterized by the overexpression of the BIM protein, which is a pro-apoptotic protein that promotes cell death. BIM protein has been shown to have both tumor-suppressive and tumor-promoting roles, depending on the context. High BIM expression: Melanoma, lung, breast, colorectal. Low BIM expression: Leukemia, Lymphoma, Prostate The expression of BIM can serve as a prognostic marker in several cancers. Higher levels of BIM are often associated with increased apoptosis and better treatment responses, while lower levels may indicate resistance to therapy and poorer outcomes. |
| Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression. TP53 is the most commonly mutated gene in human cancer. HH↑, GLI-1↑, SHH↑ P53↓ The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca. It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma. Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer. It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress. Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC. |
| 1563- | Api, | MET, | Metformin-induced ROS upregulation as amplified by apigenin causes profound anticancer activity while sparing normal cells |
| - | in-vitro, | Nor, | HDFa | - | in-vitro, | PC, | AsPC-1 | - | in-vitro, | PC, | MIA PaCa-2 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | LNCaP | - | in-vivo, | NA, | NA |
| 462- | CUR, | Curcumin promotes cancer-associated fibroblasts apoptosis via ROS-mediated endoplasmic reticulum stress |
| - | in-vitro, | Pca, | PC3 |
| 87- | QC, | Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 4501- | SeNPs, | Mechanisms of the Cytotoxic Effect of Selenium Nanoparticles in Different Human Cancer Cell Lines |
| - | in-vitro, | GBM, | A172 | - | in-vitro, | Colon, | Caco-2 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | L929 |
| 1469- | SFN, | Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | LNCaP | - | in-vivo, | Pca, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:22 Cells:% prod#:% Target#:483 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid